Trillium Therapeutics Inc.

87 articles with Trillium Therapeutics Inc.

• Pfizer Completes Acquisition of Trillium Therapeutics

  11/17/2021

  Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Trillium Therapeutics.

• Trillium Securityholders Approve Acquisition by Pfizer

  10/26/2021

  Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its securityholders approved a statutory arrangement with PF Argentum ULC (“PF Argentum”) a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) (“Pfizer”) at the special meeting of Trillium securityholders today.

• Pfizer to Acquire Trillium Therapeutics Inc.

  8/23/2021

  Pfizer Inc. and Trillium Therapeutics Inc. announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer.

• 

  Pfizer Bets $2.26 Billion on Trillium's Checkpoint Inhibitors

  8/23/2021

  ​Under the terms of the deal, Pfizer is picking up all outstanding shares of Trillium that it doesn’t already own for $18.50 per share in cash. 

• Trillium Therapeutics Reports Second Quarter 2021 Operating and Financial Results

  8/13/2021

  Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported financial and operating results for the three and six months ended June 30, 2021.

• Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine in TP53-Mutated Acute Myeloid Leukemia

  8/9/2021

  Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced that it has dosed the first TP53-mutated acute myeloid leukemia patient with TTI-622, an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine.

• Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine and Venetoclax in TP53-Wild Type Acute Myeloid Leukemia

  7/6/2021

  Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced that it has dosed the first acute myeloid leukemia patient with TTI-622, an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine and venetoclax.

• Trillium Therapeutics Appoints Catherine Mackey, Ph.D., to Its Board of Directors

  6/30/2021

  Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the appointment of pharmaceutical industry leader Catherine Mackey, Ph.D., to its Board of Directors, effective immediately.

• Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-621 in Combination With Doxorubicin in Leiomyosarcoma

  6/29/2021

  Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced that it has dosed the first patient with TTI-621, an investigational checkpoint inhibitor of the innate immune system, in combination with doxorubicin in a Phase 1b/2 study in leiomyosarcoma.

• Trillium Therapeutics Joins Russell 2000® and 3000® Indices

  6/25/2021

  Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, joins the broad-market Russell 2000® and 3000® Indices effective after the US market opens on June 28.

• Trillium Announces Voting Results From the Annual General and Special Meeting of Shareholders

  6/9/2021

  Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual General and Special Meeting of Shareholders held on June 8, 2021.

• Trillium Therapeutics Reports First Quarter 2021 Operating and Financial Results

  5/7/2021

  Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three months ended March 31, 2021. All financial amounts in this news release are in United States dollars, unless otherwise stated.

• Trillium Therapeutics Provides Data Update, Announces Phase 1b/2 Program Priorities Across Hematologic Malignancies and Solid Tumors, and Reports Governance Changes

  4/28/2021

  Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a data update, announced Phase 1b/2 program priorities across seven hematologic and solid tumor indications, and reported governance changes with its Board of Directors.

• Trillium Therapeutics Announces Dosing of First Patient in Phase 1b Study of TTI-622 in Combination With Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

  4/28/2021

  Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first multiple myeloma patient with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune system, in combination with the proteasome inhibitor carfilzomib and dexamethasone.

• Trillium Therapeutics to Host Virtual R&D Day for Investors on April 28, 2021

  4/22/2021

  Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced that it will host its virtual R&D Day for analysts and investors at 10:00 a.m. – 1:00 p.m. ET on Wednesday, April 28, 2021.

• Trillium Therapeutics Reports Annual Operating and Financial Results and Sets Date for R&D Day

  3/18/2021

  Trillium Therapeutics Inc. (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results, including an update on its CD47 clinical programs, for the year ended December 31, 2020.

• Trillium Therapeutics Presented Clinical Data at the 62nd ASH Annual Meeting and Provides Guidance for 2021

  12/7/2020

  Trillium Therapeutics Inc. ( “ Trillium ” or the “ Company ” ) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, recently presented at the American Society of Hematology (ASH) Annual Meeting, taking place virtually from December 5-8, 2020, and provides guidance for 2021. “Our presentations at ASH, as of a data cutoff of November 3, build upon our last co

• Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting

  11/25/2020

  Trillium Therapeutics Inc. announced the presentation of clinical data at the upcoming American Society of Hematology Annual Meeting, which is being held virtually from December 5-8, 2020.

• Trillium Therapeutics Reports Third Quarter 2020 Financial and Operating Results

  11/16/2020

  Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported financial and operating results for the nine months ended September 30, 2020.

• Trillium Therapeutics Appoints Paolo Pucci to Its Board of DirectorsIndustry Veteran Brings Deep Executive and Commercial Experience to Trillium Board

  11/12/2020

  Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical industry leader Paolo Pucci to its Board of Directors, effective immediately